Dizal Pharmaceutical Executives Including CFO Lu Hongbin Plan to Reduce Shareholdings

Deep News09-24 20:01

Dizal Pharmaceutical has released a new announcement stating that five senior executives, including Chief Financial Officer Lu Hongbin, Deputy General Manager Chen Suqin, QINGBEIZENG, HONCHUNGTSUI, and SHIH-YINGCHANG, plan to reduce part of their shareholdings through centralized bidding due to personal funding needs during the period from November 2, 2026 to February 1, 2027.

According to the announcement, Lu Hongbin plans to reduce no more than 60,604 shares, representing 0.0131% of the company's total share capital; Chen Suqin plans to reduce no more than 110,125 shares, representing 0.0237%; QINGBEIZENG plans to reduce no more than 81,250 shares, representing 0.0175%; HONCHUNGTSUI plans to reduce no more than 81,250 shares, representing 0.0175%; and SHIH-YINGCHANG plans to reduce no more than 15,761 shares, representing 0.0034%.

The number of shares to be reduced by each individual does not exceed 25% of their respective current holdings, with the shares mainly originating from the exercise of equity incentive plans, while Lu Hongbin additionally holds some shares obtained through secondary market purchases. This share reduction plan is a normal reduction behavior driven by the executives' personal funding needs and will not have an impact on the company's governance or ongoing operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132416534?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132416534","market":"fut","top_or_hot":-1,"title":"Dizal Pharmaceutical Executives Including CFO Lu Hongbin Plan to Reduce Shareholdings","media":"Deep News","content":"<p>Dizal Pharmaceutical has released a new announcement stating that five senior executives, including Chief Financial Officer Lu Hongbin, Deputy General Manager Chen Suqin, QINGBEIZENG, HONCHUNGTSUI, and SHIH-YINGCHANG, plan to reduce part of their shareholdings through centralized bidding due to personal funding needs during the period from November 2, 2026 to February 1, 2027.<br><br>According to the announcement, Lu Hongbin plans to reduce no more than 60,604 shares, representing 0.0131% of the company's total share capital; Chen Suqin plans to reduce no more than 110,125 shares, representing 0.0237%; QINGBEIZENG plans to reduce no more than 81,250 shares, representing 0.0175%; HONCHUNGTSUI plans to reduce no more than 81,250 shares, representing 0.0175%; and SHIH-YINGCHANG plans to reduce no more than 15,761 shares, representing 0.0034%.<br><br>The number of shares to be reduced by each individual does not exceed 25% of their respective current holdings, with the shares mainly originating from the exercise of equity incentive plans, while Lu Hongbin additionally holds some shares obtained through secondary market purchases. This share reduction plan is a normal reduction behavior driven by the executives' personal funding needs and will not have an impact on the company's governance or ongoing operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal Pharmaceutical Executives Including CFO Lu Hongbin Plan to Reduce Shareholdings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal Pharmaceutical Executives Including CFO Lu Hongbin Plan to Reduce Shareholdings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-24 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dizal Pharmaceutical has released a new announcement stating that five senior executives, including Chief Financial Officer Lu Hongbin, Deputy General Manager Chen Suqin, QINGBEIZENG, HONCHUNGTSUI, and SHIH-YINGCHANG, plan to reduce part of their shareholdings through centralized bidding due to personal funding needs during the period from November 2, 2026 to February 1, 2027.<br><br>According to the announcement, Lu Hongbin plans to reduce no more than 60,604 shares, representing 0.0131% of the company's total share capital; Chen Suqin plans to reduce no more than 110,125 shares, representing 0.0237%; QINGBEIZENG plans to reduce no more than 81,250 shares, representing 0.0175%; HONCHUNGTSUI plans to reduce no more than 81,250 shares, representing 0.0175%; and SHIH-YINGCHANG plans to reduce no more than 15,761 shares, representing 0.0034%.<br><br>The number of shares to be reduced by each individual does not exceed 25% of their respective current holdings, with the shares mainly originating from the exercise of equity incentive plans, while Lu Hongbin additionally holds some shares obtained through secondary market purchases. This share reduction plan is a normal reduction behavior driven by the executives' personal funding needs and will not have an impact on the company's governance or ongoing operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1132416534","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132416534","pubTimestamp":1790251288,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Dizal Pharmaceutical has released a new announcement stating that five senior executives, including Chief Financial Officer Lu Hongbin, Deputy General Manager Chen Suqin, QINGBEIZENG, HONCHUNGTSUI,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1574":"生物医药B类股","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"包括首席财务官卢宏斌在内的迪扎尔制药高管计划减持股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1},"content_text":"Dizal Pharmaceutical has released a new announcement stating that five senior executives, including Chief Financial Officer Lu Hongbin, Deputy General Manager Chen Suqin, QINGBEIZENG, HONCHUNGTSUI, and SHIH-YINGCHANG, plan to reduce part of their shareholdings through centralized bidding due to personal funding needs during the period from November 2, 2026 to February 1, 2027.According to the announcement, Lu Hongbin plans to reduce no more than 60,604 shares, representing 0.0131% of the company's total share capital; Chen Suqin plans to reduce no more than 110,125 shares, representing 0.0237%; QINGBEIZENG plans to reduce no more than 81,250 shares, representing 0.0175%; HONCHUNGTSUI plans to reduce no more than 81,250 shares, representing 0.0175%; and SHIH-YINGCHANG plans to reduce no more than 15,761 shares, representing 0.0034%.The number of shares to be reduced by each individual does not exceed 25% of their respective current holdings, with the shares mainly originating from the exercise of equity incentive plans, while Lu Hongbin additionally holds some shares obtained through secondary market purchases. This share reduction plan is a normal reduction behavior driven by the executives' personal funding needs and will not have an impact on the company's governance or ongoing operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132416534","isCrawlerRequest":true}